"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 3 | 2 | 5 |
| 2000 | 2 | 2 | 4 |
| 2002 | 6 | 1 | 7 |
| 2003 | 3 | 1 | 4 |
| 2004 | 1 | 4 | 5 |
| 2005 | 1 | 5 | 6 |
| 2006 | 6 | 2 | 8 |
| 2007 | 4 | 2 | 6 |
| 2008 | 7 | 8 | 15 |
| 2009 | 4 | 1 | 5 |
| 2010 | 3 | 3 | 6 |
| 2011 | 9 | 6 | 15 |
| 2012 | 3 | 5 | 8 |
| 2013 | 8 | 4 | 12 |
| 2014 | 13 | 8 | 21 |
| 2015 | 10 | 4 | 14 |
| 2016 | 6 | 2 | 8 |
| 2017 | 8 | 2 | 10 |
| 2018 | 10 | 6 | 16 |
| 2019 | 3 | 6 | 9 |
| 2020 | 9 | 3 | 12 |
| 2021 | 5 | 4 | 9 |
| 2022 | 2 | 2 | 4 |
| 2023 | 1 | 3 | 4 |
| 2024 | 6 | 2 | 8 |
| 2025 | 3 | 4 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenstr?m macroglobulinemia. Blood Adv. 2025 Oct 14; 9(19):4842-4847.
-
Revisiting the Effect of Udenafil on Exercise Performance in Patients With Fontan Circulation: Results of a Post Hoc Analysis of the FUEL Trial. J Am Heart Assoc. 2025 Aug 19; 14(16):e041348.
-
Design and Synthesis of Potent and Selective Urea-linked Benzenesulfonamide Analogs as Carbonic Anhydrase II Inhibitors. Eur J Pharm Sci. 2025 Oct 01; 213:107233.
-
Dosing Reliability of Direct Thrombin Inhibitors in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. ASAIO J. 2025 Sep 01; 71(9):691-700.
-
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenstr?m macroglobulinaemia. Br J Haematol. 2025 Jun; 206(6):1604-1614.
-
Methylated Arginine Metabolites as Biomarkers for Clinical Status and Response to Type 5 Phosphodiesterase Inhibition in Patients With Fontan Circulation. J Am Heart Assoc. 2025 Apr; 14(7):e038061.
-
How I treat patients with AML using azacitidine and venetoclax. Blood. 2025 Mar 20; 145(12):1237-1250.
-
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025 Mar 13; 145(11):1126-1135.
-
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood. 2025 Mar 06; 145(10):1047-1060.
-
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025 Feb 11; 9(3):617-626.